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Background
It has always been an objective of process development
and more recently it has also become a regulatory
expectation to build robustness into and demonstrate
proper control of a manufacturing process, thus ensur-
ing that the biological product meets consistently its
quality attributes and specifications. This is achieved
mainly through systematic process development and
understanding. Once a process is locked and ahead of
consistency runs at the intended commercial scale, pro-
cess characterization studies (PCS hereafter) further
contribute to the demonstration of process robustness
and the justification of process control ranges. These
studies characterize the relationship between process
parameters and process performance as well as product
quality attributes. For practical reasons PCS are per-
formed in a scale down model (SDM hereafter) of the
manufacturing process studied. Therefore, it is essential
to establish a SDM that is representative of the com-
mercial scale.
Here we describe a road map for developing a scale
down model of a cell culture process for recombinant
protein production. The cell culture process modeled
was a 12,000 L scale fed batch process producing a
monoclonal antibody.
Methods
In a first step, the SDM was defined such that volume-
dependent parameters (medium and feeds volumes,
working volumes) were scaled down linearly and
volume-independent ones (temperature, dissolved oxy-
gen, pH, cell age) were kept at the same set-points as in
the commercial scale bioreactor. Some cell culture pro-
cess parameters such as agitation and aeration are diffi-
cult to scale down linearly due to bioreactor and sparger
geometry and differences in controller systems. Hence
determination of these parameters was first done by
engineering scale down considerations. These considera-
tions determined a theoretical small scale model used
for proof of concept experiments. Process performance
in initial scale down runs was then compared to com-
mercial scale production in terms of cell growth, key
metabolites, product accumulation.
Two main deliverables were defined for the SDM:
1. The model should exhibit process performance
comparable to the commercial scale process. This was
necessary to study the effects of input parameter varia-
tions during PCS.
A way of assessing process performance is by moni-
toring in-process parameters during the SDM runs and
comparing them to commercial scale batch data. Here
the following evaluation parameters were chosen:
￿ Viable cell density and viabilities
￿ Metabolism indicators (namely off-line pH, dCO2,
osmolality, glucose and lactate concentrations)
￿ Product titer
2. The model should deliver material with product
quality attributes comparable to the material produced
at the corresponding manufacturing scale process step
(post cell harvest). This was necessary to study the
effects of parameter changes on upstream product
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selected product quality specifications for the commer-
cial scale batches. Namely:
￿ Oligosaccharide profiles
￿ Monomer/aggregate/fragment proportions
￿ Monomer,- Heavy-and Light chain patterns
￿ Acidic peak group species proportions
Results
Proof of concept bioreactor runs using the theoretical
SDM showed good comparability between the model and
the commercial scale regarding process performance;
however it was observed that the dissolved CO2 values
were lower than in commercial scale. We consider this to
be a consequence of geometrical bioreactor differences.
The liquid surface-to-volume ratio is significantly higher
in small scale than it is in large scale. Furthermore in
small scale bioreactors a higher maximum volumetric gas
flow rate was employed to compensate for a reduced gas
bubble residence time. These two main differences
resulted in increased CO2 stripping.
An overlay flow containing 6 % CO2 was applied to
the headspace of the 2 L vessels to reduce the stripping
(fine –tuning).
After establishing the CO2 overlay as part of the aera-
tion strategy, three SDM verification runs were carried
out. Cell growth, cell metabolism and Mab titers were
monitored throughout the cultures. Lab scale data
resulting from daily sampling was mostly within the
average ± 3 x standard deviation (SD) of the commercial
scale data and therefore comparable.
Scale down model harvest material was compared to har-
vest material from the commercial scale with regards to
their product quality attributes. The clarified cell culture
fluid from both scales was protein A purified in laboratory
scale and product quality was assessed (Table 1).
Conclusions
Good comparability regarding process performance of
the production bioreactor between the SDM runs and
large scale data was demonstrated. Growth data, product
titer, pH, osmolality, glucose and lactate profiles all
showed the same trends. The tested output parameters
where mostly within ± 3 x SD of the average commer-
cial scale data.
Product quality attributes of scale down samples were
comparable to commercial scale product quality as
shown by comparison with clarified cell culture fluid
samples from commercial scale.
The verification results demonstrate that the systema-
tic scale down approach applied in this work provided a
laboratory scale model that was representative of the
commercial scale process in terms of process perfor-
mance and product quality of the generated material
and was therefore suitable to be used in process charac-
terization studies.
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Table 1 Product quality attributes of purified harvest material
Product quality attribute Commercial scale reference
sample
SDM verification run 1 SDM verification run 2 SDM verification run 3






Purity by size exclusion HPLC
Monomer [%] 99 100 99 99
Aggregate [%] 1 0 0 1
Fragment [%] 0 0 1 0
Monomer pattern by capillary gel electrophoresis
Monomer [%] 97 97 97 97
Light and heavy chain pattern by capillary gel electrophoresis
Light chain + heavy chain
[%]
99 99 98 99
Acidic species by cation exchange chromatography
Acidic species [%] 30 30 28 32
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